Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04548648 · OUTCOME

Number of Participants With Serious Adverse Events

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas · Source last updated 2026-06-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
up to 3 years

What was measured

All treatment-attributed adverse events and toxicities will be assessed, classified, and graded in accordance with the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

Groups in this outcome

Open-label, Single-arm

Subjects with relapsed primary central nervous system lymphoma (PCNSL) or relapsed secondary CNS lymphoma (SCNSL) without systemic disease will receive acalabrutinib until disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Open-label, Single-arm10

Reported measurements

spinal cord compression
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Open-label, Single-arm1Not reportedNot reportedNot reportedNot reported
wound infection
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Open-label, Single-arm1Not reportedNot reportedNot reportedNot reported
Gait disturbance
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Open-label, Single-arm1Not reportedNot reportedNot reportedNot reported
Aphasia
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Open-label, Single-arm1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    spinal cord compression
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    wound infection
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Gait disturbance
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Aphasia
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
All treatment-attributed adverse events and toxicities will be assessed, classified, and graded in accordance with the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.
groups
  1. description
    Subjects with relapsed primary central nervous system lymphoma (PCNSL) or relapsed secondary CNS lymphoma (SCNSL) without systemic disease will receive acalabrutinib until disease progression or unacceptable toxicity.
    id
    OG000
    title
    Open-label, Single-arm
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
up to 3 years
title
Number of Participants With Serious Adverse Events
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice